Zymeworks Inc. (ZYME)
NASDAQ: ZYME · Real-Time Price · USD
13.95
-0.60 (-4.12%)
Nov 21, 2024, 10:54 AM EST - Market open
Zymeworks Employees
As of December 31, 2023, Zymeworks had 278 total employees, including 272 full-time and 6 part-time employees. The number of employees decreased by 16 or -5.44% compared to the previous year.
Employees
278
Change (1Y)
-16
Growth (1Y)
-5.44%
Revenue / Employee
$223,737
Profits / Employee
-$408,888
Market Cap
960.84M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Brookdale Senior Living | 36,000 |
The Pennant Group | 5,791 |
HealthStream | 1,092 |
Weave Communications | 844 |
Collegium Pharmaceutical | 197 |
Cogent Biosciences | 164 |
Avadel Pharmaceuticals | 154 |
Pulse Biosciences | 56 |
ZYME News
- 4 hours ago - Zymeworks Announces Participation in Upcoming Investor Conferences - GlobeNewsWire
- 5 hours ago - FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC) - GlobeNewsWire
- 16 days ago - Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Folate Receptor-⍺ Expressing Advanced Solid Tumors - GlobeNewsWire
- 17 days ago - Zymeworks: Turning The Tide With 2 Key Milestones For Zanidatamab - Seeking Alpha
- 20 days ago - Zymeworks Inc. (ZYME) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 23 days ago - Zymeworks Announces Participation in Upcoming Investor Conferences - GlobeNewsWire
- 27 days ago - Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference - GlobeNewsWire
- 4 weeks ago - Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing Cancers - GlobeNewsWire